Search alternatives:
significant potential » significant positive (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
cause decrease » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
Showing 41 - 60 results of 63,850 for search '(( significant cause decrease ) OR ( significant potential increased ))', query time: 0.96s Refine Results
  1. 41
    Digestive glycosyl hydrolase activities after fungal inoculation to <i>Ceratitis capitata</i> (24 to 144 hours post-inoculation).

    Digestive glycosyl hydrolase activities after fungal inoculation to <i>Ceratitis capitata</i> (24 to 144 hours post-inoculation). by Wafa Djobbi (5180810)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 42
    Expression of 7 immune genes in <i>Ceratitis capitata</i> inoculated with <i>P</i>. <i>lilacinum</i> for the times analyzed (0h, 24h, 72h, and 144h).

    Expression of 7 immune genes in <i>Ceratitis capitata</i> inoculated with <i>P</i>. <i>lilacinum</i> for the times analyzed (0h, 24h, 72h, and 144h). by Wafa Djobbi (5180810)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 43
    Digestive disaccharide and polysaccharide activities after fungal inoculation to <i>Ceratitis capitata</i> (24 to 144 hours post-inoculation).

    Digestive disaccharide and polysaccharide activities after fungal inoculation to <i>Ceratitis capitata</i> (24 to 144 hours post-inoculation). by Wafa Djobbi (5180810)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 44
    Metabolites with significantly increased abundance in murine nasopharynx vs lungs.

    Metabolites with significantly increased abundance in murine nasopharynx vs lungs. by Angharad E. Green (9667606)

    Published 2023
    Save to List
    Saved in:
  5. 45
    Metabolites with significantly increased abundance in murine lungs vs nasopharynx.

    Metabolites with significantly increased abundance in murine lungs vs nasopharynx. by Angharad E. Green (9667606)

    Published 2023
    Save to List
    Saved in:
  6. 46
    Key genes pathway identification and potential drug design.

    Key genes pathway identification and potential drug design. by Md. Numan Islam (13514308)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 47
    Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.

    Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

    Published 2021
    Save to List
    Saved in:
  8. 48
    Significant decrease of the coiled-coil score in the double proline-substituted CAHS3 mutant.

    Significant decrease of the coiled-coil score in the double proline-substituted CAHS3 mutant. by Akihiro Tanaka (342394)

    Published 2022
    Save to List
    Saved in:
  9. 49
    Functional associations with low and increased stroke risk based on CHA<sub>2</sub>DS<sub>2</sub>VASc.

    Functional associations with low and increased stroke risk based on CHA<sub>2</sub>DS<sub>2</sub>VASc. by Maurice Pradella (11678817)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 50
    Baseline and post-treatment results of categorical electrocardiographic variables in each study group.

    Baseline and post-treatment results of categorical electrocardiographic variables in each study group. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 51
    Line graph showing the values of inflammatory cytokines at baseline and after treatment.

    Line graph showing the values of inflammatory cytokines at baseline and after treatment. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 52
    Baseline and Post-Treatment Myocardial Perfusion Defects Expressed as a Percentage of the Total Left Ventricular Surface Area in Each Experimental Group.

    Baseline and Post-Treatment Myocardial Perfusion Defects Expressed as a Percentage of the Total Left Ventricular Surface Area in Each Experimental Group. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 53
    Baseline and post-treatment results of quantitative electrocardiographic variables in each study group.

    Baseline and post-treatment results of quantitative electrocardiographic variables in each study group. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 54
    CONSORT diagram illustrating patient flow during the study.

    CONSORT diagram illustrating patient flow during the study. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 55
    Baseline and Post-Treatment Results of Echocardiographic Variables in Each Experimental Group.

    Baseline and Post-Treatment Results of Echocardiographic Variables in Each Experimental Group. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 56
    Illustrative images of the processing of a myocardial perfusion study in a patient with Chagas disease.

    Illustrative images of the processing of a myocardial perfusion study in a patient with Chagas disease. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 57
    Clinical and Demographic Characteristics of the Study Population.

    Clinical and Demographic Characteristics of the Study Population. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 58
    Illustrative images of the quantitative processing of polar maps from a myocardial perfusion study in one of the investigated patients.

    Illustrative images of the quantitative processing of polar maps from a myocardial perfusion study in one of the investigated patients. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 59
    Baseline and Post-Treatment Serum Cytokine Levels in Each Investigational Group.

    Baseline and Post-Treatment Serum Cytokine Levels in Each Investigational Group. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 60
    Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group.

    Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group. by Káryta Suely Macêdo Martins (22404155)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: